▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #780 by analyst upside · 2026-06-27
IOVA
Iovance Biotherapeutics, Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+107.1%
implied upside to consensus target
Current Price $4.25
Consensus Target $8.8
Bull Target $14.0
Bear Target $4.0
Analysts Covering 10
ANALYST CONSENSUS — BUY
Strong Buy
2
Buy
5
Hold
3
Sell
0
52-Week Low $1.66
52-Week High $5.63
YTD Return +68.7%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E -13.3x
EPS (TTM) $-0.92
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $286M
Profit Margin -123.9%
52-WEEK RANGE
52-Week Low $1.66
52-Week High $5.63
Current Price $4.25
Bear Target $4.0
Bull Target $14.0
● Now $4.25 ● Target $8.8
TRADING DATA
Avg Volume 14.4M
YTD Return +68.7%
Analyst Count 10
Consensus Buy
Upside to Target +107.1%
Last Updated 2026-06-27

ANALYST SUMMARY

Iovance Biotherapeutics, Inc. (IOVA) is currently trading at $4.25 with a Wall Street consensus price target of $8.8, implying potential upside of 107.1% over the next 12 months. 10 analysts currently cover IOVA, with a consensus rating of Buy — 70% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $14.0, while the most cautious has a target of $4.0.

IOVA operates in the Healthcare sector with a market capitalisation of $2B. The stock is up 68.7% year-to-date and is currently trading near the upper end of its 52-week range of $1.66 – $5.63.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ADMA +101.1%
ADMA Biologics, Inc.
$2B · P/E 12.9x · Buy
GTBIF +112.0%
Green Thumb Industries Inc.
$2B · P/E 14.2x · Buy
HCM +124.5%
HUTCHMED (China) Limited
$2B · P/E 3.9x · Buy
TMDX +71.4%
TransMedics Group, Inc.
$2B · P/E 15.7x · Buy
INVA +50.6%
Innoviva, Inc.
$2B · P/E 3.8x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for IOVA, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Chardan Capital — Reiterated
Buy → Buy 2026-05-08 33% win rate (6 calls)
Chardan Capital — Reiterated
Buy → Buy 2026-04-10 33% win rate (6 calls)
UBS — Reiterated
Neutral → Neutral 2026-03-05 33% win rate (6 calls)
Citizens ↑ Upgrade
Market Perform → Market Outperform 2026-03-03 Building track record
Barclays — Reiterated
Overweight → Overweight 2026-02-25 Building track record
Citizens ↑ Upgrade
Market Perform → Market Outperform 2026-02-25 Building track record
Barclays — Reiterated
Overweight → Overweight 2025-12-17 Building track record
Barclays — Reiterated
Overweight → Overweight 2025-11-24 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
—
out of 100
Coverage depth
0/30
Consensus clarity
0/30
Vote unanimity
0/25
Rating stability
0/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call — not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →